Diego Villa

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP

Norbert Schmitz, Samira Zeynalova, Maike Nickelsen et al. · Journal of Clinical Oncology · 2016 · 445 citations

Medicine, Oncology, Chemotherapy +13

Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

Vivien Mak, Jeremey Hamm, Mukesh Chhanabhai et al. · Journal of Clinical Oncology · 2013 · 428 citations · Full text

Medicine, Hematology, Oncology +15

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

Daisuke Ennishi, Aixiang Jiang, Merrill Boyle et al. · Journal of Clinical Oncology · 2018 · 420 citations

Medicine, Hematology, Oncology +17

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan et al. · The Lancet Oncology · 2015 · 410 citations

Medicine, Immunology, Pharmacotherapy +12

Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy

Diego Villa, Joseph M. Connors, Tamara Shenkier et al. · Annals of Oncology · 2009 · 217 citations · Full text

Medicine, Neurology, Oncology +14